Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific to $60 from $56 and keeps a Strong Buy rating on the shares. Boston Scientific is an above-average grower both on revenue and EPS with a pipeline that could accelerate the growth profile, and drive multiple expansion, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSX:
- Needham med tech analysts to hold an analyst/industry conference call
- Boston Scientific added to ‘Tactical Outperform’ list at Evercore ISI
- Boston Scientific price target raised to $60 from $54 at Citi
- Boston Scientific enters strategic partnership with Scivita Medical in China
- Boston Scientific initiated with a Buy at UBS